BALCHEM CORP

Balchem Corporation develops, manufactures, distributes and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, plant nutrition, sterilization, fumigation, and industrial markets. The company operates through three reportable segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. The filing does not disclose an overall market size or growth rate for the industries in which Balchem operates.

Competitors include many large and small companies, some with greater financial, research and development, production and other resources. Competition in the supplement, food and beverage markets is based primarily on product performance, customer support, quality, service and price. In the animal feed and industrial markets, competition is based primarily on product performance, customer support, quality, service and price, and these markets are highly price competitive. In the Specialty Products segment, competition within Performance Gases is based primarily on service, reliability, quality, and price. In the plant nutrition business, competition is based primarily on product performance, customer support, quality, and price. The filing does not provide specific market share percentages or relative standing for the company versus its competitors.

The company generates revenue through the sale of specialty performance ingredients and products. Revenue is recognized when control of the promised goods is transferred to customers. The company sells products through its own sales force, independent distributors and sales agents. The filing does not provide a breakdown of recurring versus transactional income or describe platform or ecosystem dynamics.

The Human Nutrition and Health segment provides human grade choline nutrients, mineral amino acid chelated products, specialty vitamin K2, and methylsulfonylmethane (MSM). It also serves the food and beverage industry with capabilities in customized spray dried and emulsified powders, extrusion and agglomeration, blended lipid systems, liquid flavor delivery systems, juice and dairy bases, chocolate systems, ice cream bases and variegates, and microencapsulation solutions. For the year ended December 31, 2025, this segment reported net sales of $659,387 ¹ and earnings from operations of $153,906 ². The Animal Nutrition and Health segment provides nutritional products derived from microencapsulation and chelation technologies, as well as choline chloride for monogastric animal health, and MSM for pet health. For the year ended December 31, 2025, this segment reported net sales of $230,852 ³ and earnings from operations of $18,687 ⁴. The Specialty Products segment re-packages and distributes performance gases and chemicals including ethylene oxide, propylene oxide, and ammonia, and also sells chelated minerals for agricultural nutrition. For the year ended December 31, 2025, this segment reported net sales of $140,976 ⁵ and earnings from operations of $42,901 ⁶.

In late June 2025, the European Commission announced provisional duties between 95.4% and 120.8% on imports into the European Union of choline chloride originating in the People's Republic of China, effective July 1, 2025. On December 19, 2025, the European Commission published their final decision to set definitive duties between 90.0% and 115.9%. On December 9, 2025, the Board of Directors approved a new stock repurchase program authorizing the repurchase of up to and including 4,000,000 ⁷ shares of the company's ordinary shares. During 2025, the company repurchased 684,927 ⁸ shares of common stock for $107,636 ⁹. Capital expenditures were approximately $43,193 ¹⁰ for 2025. The company invested $18,820 ¹¹ on projects expected to provide favorable returns on investment, including expanded capacity in key product lines and efficiency projects in both the HNH and the ANH segments and equipment upgrades. The company also invested $5,147 ¹² for environmental, health, safety, and security upgrades to its facilities. Cash paid to acquire an existing toll manufacturer to add capacity amounted to $323 ¹³ for the year ended December 31, 2025, net of cash acquired.

For the fiscal year ended December 31, 2025, total net sales were $1,037,161 ¹⁴, compared to $953,684 ¹⁵ in 2024, an increase of 8.8% ¹⁶. Gross margin was $370,633 ¹⁷ compared to $336,206 ¹⁸ in 2024, an increase of 10.2% ¹⁹. Earnings from operations were $209,326 ²⁰ compared to $182,909 ²¹ in 2024, an increase of 14.4% ²². Net earnings were $154,845 ²³ compared to $128,475 ²⁴ in 2024, an increase of 20.5% ²⁵. Diluted net earnings per common share were $4.75 ²⁶ compared to $3.93 ²⁷ in 2024. Cash flows provided by operating activities were $216,556 ²⁸ compared to $181,999 ²⁹ in 2024, an increase of 19.0% ³⁰.

Capital expenditures are projected to range from $40,000 to $45,000 for 2026 ³¹, including continued efforts to invest in energy and water saving projects, while exploring additional renewable energy opportunities in supporting future growth and capacities.

The filing discusses the anti-dumping investigation in the European Union as a recent development. In late June 2025, the European Commission announced provisional duties between 95.4% and 120.8% on imports into the European Union of choline chloride originating in the People's Republic of China, effective July 1, 2025. On December 19, 2025, the European Commission published their final decision to set definitive duties between 90.0% and 115.9%. The filing does not quantify the expected revenue contribution or opportunity size from this development.The filing states that the company continues to invest in projects across all production facilities. Capital expenditures were approximately $43,193 ³² for 2025. The company invested $18,820 ³³ on projects expected to provide favorable returns on investment, including expanded capacity in key product lines and efficiency projects in both the HNH and the ANH segments and equipment upgrades to improve process reliability and support business growth. The company also invested $5,147 ³⁴ for environmental, health, safety, and security upgrades to its facilities.Capital expenditures are projected to range from $40,000 to $45,000 for 2026 ³⁵. On December 9, 2025, the Board of Directors approved a new stock repurchase program authorizing the repurchase of up to and including 4,000,000 ³⁶ shares of the company's ordinary shares.The filing discusses risks related to supply chain disruptions due to political unrest, terrorist acts, and national and international conflicts, including Russia's invasion of Ukraine and the ongoing conflict in the Middle East, which may increase the likelihood of already strained supply interruptions and further hinder the company's ability to access materials and energy. The filing also notes that in 2025, supply reliability stabilized, although procuring certain raw materials remained a challenge due to the ongoing geopolitical environment impacting some supply lanes. The company experienced inflationary patterns in 2025, including from certain tariffs, in several categories that it sources.

The filing discusses regulatory headwinds related to ethylene oxide (EtO). In January 2025, the EPA issued its Interim Decision whereby EtO was re-registered for the sterilization of medical devices and the reduction of microbes on certain spices/seasonings. The ID provides for a phase-out period for the use of EtO on certain spices, discontinues minor applications, and includes mitigation and monitoring measures impacting product users, including the company's customers, with phased compliance deadlines ranging from several months to ten years. The filing states that if the ID and other requirements remain unchanged, such requirements will likely result in increased costs and regulatory burdens.

The company faces material risks from regulatory actions concerning ethylene oxide (EtO). In January 2025, the EPA issued its Interim Decision which provides for a phase-out period for the use of EtO on certain spices and includes mitigation measures with compliance deadlines ranging from several months to ten years. Any future determination by the EPA to discontinue permitted use of ethylene oxide would have a material adverse effect on the company's business and financial results. The company also faces risks from the anti-dumping investigation in the European Union, where definitive duties between 90.0% and 115.9% have been set on imports of choline chloride originating in China. Additionally, the company's Verona, Missouri facility is a Superfund site, and in January 2025, BCP agreed to pay a $300 ³⁷ civil penalty, invest in a new scrubber system, and spend $350 ³⁸ to implement community benefit projects to resolve alleged Clean Air Act violations. The company also faces risks from raw material price fluctuations, as raw materials are derived from petrochemicals, minerals, metals, agricultural goods and other commodities subject to price fluctuations, and the company experienced inflationary patterns in 2025 including from certain tariffs.

Management's discussion emphasizes that the company develops, manufactures, distributes and markets specialty performance ingredients and products. The overall tone is forward-looking, with management stating that they expect operations to continue generating sufficient cash flow to fund working capital requirements and necessary capital investments. Management states they are actively pursuing additional acquisition candidates. Management notes that capital expenditures are projected to range from $40,000 to $45,000 for 2026 ³⁹, including continued efforts to invest in energy and water saving projects, while exploring additional renewable energy opportunities in supporting future growth and capacities. The strategic priorities emphasized include investing in projects across all production facilities, with $18,820 ⁴⁰ invested in 2025 on projects expected to provide favorable returns on investment including expanded capacity in key product lines and efficiency projects, and $5,147 ⁴¹ invested for environmental, health, safety, and security upgrades.